University of Rome "Tor Vergata", Policlinico Tor Vergata, Neurophysiopathology Department, Italy.
Epilepsy Behav. 2013 Feb;26(2):170-4. doi: 10.1016/j.yebeh.2012.11.049. Epub 2013 Jan 9.
The purpose of this study was to evaluate the effects of zonisamide (ZNS) as adjunctive therapy on sleep-wake cycle and daytime somnolence in adult patients affected by focal epilepsy.
Thirteen patients affected by focal epilepsy were recruited to undergo a 24-hour ambulatory polysomnography, Multiple Sleep Latency Test (MSLT), and a subjective evaluation of nocturnal sleep by means of the Pittsburgh Sleep Quality Index (PSQI) and daytime somnolence by means of the Epworth Sleepiness Scale (ESS) before and after 3 months of treatment with ZNS as add-on therapy.
Twelve patients completed the study. Zonisamide therapy reduced seizures by >50% in 8 out of 12 patients. Zonisamide did not induce any significant changes in nocturnal polysomnographic variables and in PSQI scores. In addition, mean sleep latency and ESS score were unmodified after treatment.
Zonisamide seems to be effective and safe in focal epilepsy. Both subjective and objective sleep parameters showed no detrimental effects on nocturnal sleep and daytime somnolence in patients with focal epilepsy using ZNS. Since some AEDs induce sleep impairment, which is known to trigger EEG abnormalities and seizures and to worsen quality of life, our findings suggest a positive profile of ZNS.
本研究旨在评估佐米曲普坦（ZNS）作为附加治疗对成人局灶性癫痫患者睡眠-觉醒周期和日间嗜睡的影响。
招募了 13 名局灶性癫痫患者，在接受佐米曲普坦（ZNS）辅助治疗 3 个月前后，进行了 24 小时动态多导睡眠图、多次睡眠潜伏期试验（MSLT）和匹兹堡睡眠质量指数（PSQI）主观评估夜间睡眠，以及通过 Epworth 嗜睡量表（ESS）评估日间嗜睡。
12 名患者完成了研究。佐米曲普坦治疗使 12 名患者中的 8 名患者的癫痫发作减少了>50%。佐米曲普坦治疗未导致夜间多导睡眠图变量和 PSQI 评分发生任何显著变化。此外，治疗后平均睡眠潜伏期和 ESS 评分也没有改变。
佐米曲普坦在局灶性癫痫中似乎是有效和安全的。佐米曲普坦对使用佐米曲普坦的局灶性癫痫患者的夜间睡眠和日间嗜睡的主观和客观睡眠参数均无不良影响。由于一些抗癫痫药物会引起睡眠障碍，已知这会引发脑电图异常和癫痫发作，并降低生活质量，因此我们的研究结果表明佐米曲普坦具有积极的作用。
